WHO ICTRP trial
Defining the optimal dose for continuous flucloxacillin infusion using…
NL-OMON43049 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON43049 |
|---|---|
| Public title | Defining the optimal dose for continuous flucloxacillin infusion using pharmacokinetic modelling ;The FLUCON-study |
| Scientific title | Defining the optimal dose for continuous flucloxacillin infusion using pharmacokinetic modelling ;The FLUCON-study - Flucon |
| Primary sponsor | Deventer Ziekenhuis |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Countries | The Netherlands |
| Conditions | infectional disease;10004018;infectional disease |
| Interventions | Part B: Patients will receive the new dosing scheme for continuous flucloxacillin therapy and TDM will be conducted. ;Flucloxacillin kinetics |
| Registration date | May 29, 2017 |
| Target size | 30 |
| Secondary IDs | 2016-000930-24;NL57100.075.16 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: